After progression on FLAURA2 for EGFR exon 19 mutated mNSCLC adenocarcinoma, biopsy shows transformation to squamous cell carcinoma with EGFR exon 19 mutation retained on tissue testing. Would you consider Amivantamab or Datopotamab in the second line setting?